NUVL
Nuvalent Inc
NASDAQ: NUVL · HEALTHCARE · BIOTECHNOLOGY
$123.96
+0.00% today
Updated 2026-07-16
Market cap
$9.81B
P/E ratio
—
P/S ratio
—
EPS (TTM)
$-6.06
Dividend yield
—
52W range
$71 – $124
Volume
2.8M
WallStSmart proprietary scores
25
out of 100
Grade: F
Strong Sell
Investment rating
4.3
Growth
C6.8
Quality
B3.0
Profitability
D5.0
Valuation
C+1/9
Piotroski F-Score
Weak
3.7
Altman Z-Score
Safe zone
—
Industry rank
—
View all highly rated stocks (75+) →210 stocks currently score above 75
Price targets
Analyst target
$124.00
+0.03%
12-Month target
—
—
Intrinsic (DCF)
—
Margin of safety
—
0 Strong Buy0 Buy17 Hold0 Sell0 Strong Sell
Price chart
Stock snapshot
Strengths
+ Altman Z 3.71 — safe zone
Risks
- Piotroski 1/9 — weak financial health
- Thin margins at 0.00%
- Negative free cash flow $-92.40M
Key financials
Revenue Net Income Free Cash Flow
| Metric | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Net income | $-73.35M | $-126.22M | $-260.76M | $-425.38M | $-109.28M |
| EPS | — | — | — | — | $-6.06 |
| Free cash flow | $-64.97M | $-99.74M | $-185.06M | $-275.21M | $-92.40M |
| Profit margin | — | — | — | — | — |
Recent insider activity
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| 2026-07-09 | PELISH, HENRY E. | Sale | 2,111 | $123.81 |
| 2026-07-06 | PORTER, JAMES RICHARD | Sale | 30,000 | — |
| 2026-07-06 | PORTER, JAMES RICHARD | Buy | 30,000 | $18.93 |
Peer comparison
Smart narrative
Nuvalent Inc trades at $123.96. Our Smart Value Score of 25/100 indicates the stock is weak. The company scores 1/9 on the Piotroski F-Score. With an Altman Z-Score of 3.71, it sits in the safe zone.
Frequently asked questions
What is Nuvalent Inc's stock price?
Nuvalent Inc (NUVL) trades at $123.96.
Is Nuvalent Inc overvalued?
Nuvalent Inc carries a Smart Value Score of 25/100 (Grade F), which we rate Strong Sell. That score blends growth, quality, and valuation into one read.
What is the price target of Nuvalent Inc (NUVL)?
The 12-month analyst consensus target is $124.00, about 0.0% above the current $123.96. A consensus target is the average of Wall Street's 12-month forecasts, so it works as a sentiment gauge rather than a guarantee, and it resets with every earnings cycle.
Altman Z-Score?
Nuvalent Inc's Altman Z-Score is 3.71, which places it in the safe zone. The Altman Z-Score gauges bankruptcy risk from profitability, leverage, and asset efficiency, and a higher reading points to lower financial distress risk.
Company info
SectorHEALTHCARE
IndustryBIOTECHNOLOGY
CountryUSA
ExchangeNASDAQ
CurrencyUSD
Quick metrics
P/S ratio—
ROE-38.32%
Beta1.14
50D MA$112.22
200D MA$103.43
Shares out0.07B
Float0.05B
Short ratio—
Avg volume2.8M
Performance
1 week—
1 month—
3 months—
YTD—
1 year—
3 years—
5 years—